Cushing's syndrome, a rare endocrine disorder characterised by prolonged exposure to excessive cortisol, presents a significant clinical dilemma due to its varied and often non-specific symptomatology. This diagnostic complexity frequently results in substantial delays between symptom onset and definitive diagnosis, impacting patient prognosis and increasing morbidity. Addressing these diagnostic and treatment gaps is critical for improving patient care, a key theme highlighted at endo 2026.
Cushing's syndrome, a condition arising from chronic glucocorticoid excess, manifests with a broad spectrum of clinical features, including central obesity, hypertension, diabetes mellitus, muscle weakness, and psychiatric disturbances. The insidious onset and non-specific nature of these symptoms frequently lead to misdiagnosis or delayed diagnosis.1 Studies indicate that the average time from symptom onset to diagnosis can range from 2 to 6 years, during which patients experience progressive deterioration in health and quality of life.1 This diagnostic lag is compounded by the rarity of the condition, leading to a lower index of suspicion among general practitioners and specialists alike. The endo 2026 conference underscored the urgent need for enhanced awareness and streamlined diagnostic pathways to mitigate these delays.
The diagnostic process for Cushing's syndrome typically involves a multi-step approach, beginning with screening tests to confirm hypercortisolism, followed by tests to determine the aetiology. Initial screening tests include 24-hour urinary free cortisol (UFC) measurement, late-night salivary cortisol, and the overnight dexamethasone suppression test (ONDST).2 A UFC level greater than 150 nmol/24h, a late-night salivary cortisol level greater than 3.6 nmol/L, or a serum cortisol level greater than 50 nmol/L after 1 mg dexamethasone are indicative of hypercortisolism.2 Once hypercortisolism is confirmed, plasma ACTH levels differentiate between ACTH-dependent and ACTH-independent causes. ACTH-dependent Cushing's syndrome, accounting for approximately 80% of cases, is most commonly due to a pituitary adenoma (Cushing's disease).3 ACTH-independent causes are typically adrenal in origin.3
Treatment Strategies and Outcomes
Treatment for Cushing's syndrome is primarily directed at normalising cortisol levels and addressing the underlying cause. Surgical resection of the tumour, whether pituitary, adrenal, or ectopic, is the preferred first-line therapy. Transsphenoidal surgery for pituitary adenomas achieves remission rates of 70% to 90% in experienced centres.4 Adrenalectomy is curative for adrenal adenomas.5 In cases where surgery is not feasible, unsuccessful, or contraindicated, medical therapies play a crucial role. These agents target various steps in the cortisol synthesis pathway or block glucocorticoid receptor action. Medications include steroidogenesis inhibitors (e.g., ketoconazole, metyrapone, osilodrostat), neuromodulators of ACTH secretion (e.g., pasireotide), and glucocorticoid receptor blockers (e.g., mifepristone).6
The long-term prognosis for patients with Cushing's syndrome is significantly influenced by the timeliness and effectiveness of treatment. Untreated or inadequately treated Cushing's syndrome is associated with increased mortality, primarily from cardiovascular events, infections, and thromboembolism.7 Normalisation of cortisol levels post-treatment can lead to resolution or improvement of many comorbidities, including hypertension, diabetes, and osteoporosis. However, some complications, such as cognitive dysfunction and psychiatric symptoms, may persist even after biochemical remission.7 The importance of early intervention cannot be overstated; prompt diagnosis and initiation of appropriate therapy are directly linked to improved patient survival and reduced long-term morbidity.7
Despite advancements in diagnostic tools and therapeutic options, challenges remain. The heterogeneity of clinical presentation and the need for specialised endocrine testing contribute to diagnostic delays. Furthermore, even after successful treatment, patients require lifelong follow-up to monitor for recurrence and manage residual comorbidities. The endo 2026 discussions emphasised the need for greater awareness campaigns among primary care physicians and the development of clear referral pathways to endocrinology specialists to expedite diagnosis and treatment initiation. Future research should focus on identifying novel biomarkers for earlier detection and developing more targeted and tolerable medical therapies.
The persistent diagnostic delay in Cushing's syndrome, often extending years, represents a significant failure in our current clinical approach. General practitioners and specialists must cultivate a heightened index of suspicion for this rare but devastating condition. When a patient presents with a constellation of seemingly disparate symptoms like new-onset hypertension, unexplained weight gain, and mood changes, Cushing's syndrome should be on the differential, not an afterthought. Relying solely on overt signs like a 'moon face' or 'buffalo hump' means missing too many patients in the earlier, more treatable stages of the disease.
The industry has a role to play beyond developing new therapies. Educational initiatives, perhaps funded by companies with treatments like osilodrostat or pasireotide, could significantly improve early recognition. These efforts should target primary care and non-endocrine specialists, providing practical algorithms for screening and referral. The current reliance on specialist-led diagnosis, while necessary for complex cases, inadvertently contributes to delays when initial suspicion is low in the broader medical community. Streamlined access to diagnostic tests, particularly late-night salivary cortisol, could also reduce the burden on patients and primary care.
Ultimately, the patient bears the brunt of these delays, enduring progressive deterioration in health and quality of life. The long-term sequelae, even after successful treatment, highlight the irreversible damage that prolonged hypercortisolism can inflict. Improving outcomes for Cushing's syndrome patients is not just about new drugs; it is fundamentally about earlier detection and intervention. This requires a collective shift in clinical mindset, moving from reactive management of advanced disease to proactive screening based on a broader understanding of its subtle presentations.
- The Pivot Cushing's syndrome diagnosis often faces delays of 2 to 6 years, hindering timely intervention.
- The Data Early diagnosis and treatment initiation correlate with improved long-term outcomes and reduced comorbidity burden.
- The Action Clinicians should maintain a high index of suspicion for Cushing's syndrome in patients presenting with multiple, seemingly unrelated symptoms.
ART-2026-311
Cite This Article
Team TLSFE. Cushing's syndrome: addressing diagnostic delays and treatment gaps. The Life Science Feed. Updated June 13, 2026. Accessed June 13, 2026. https://thelifesciencefeed.com/endocrinology/adrenal-gland-diseases/news/cushings-syndrome-addressing-diagnostic-delays-and-treatment-gaps.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. Nieman LK. Cushing's syndrome: update on diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes. 2015;22(4):306-311.
2. Arnaldi G, et al. Diagnosis and Complications of Cushing's Syndrome: A Consensus Statement. J Clin Endocrinol Metab. 2003;88(12):5593-5602.
3. Lacroix A, et al. Cushing's syndrome. Lancet. 2015;386(9996):913-927.
4. Biller BM, et al. Treatment of Cushing's Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(11):3703-3714.
5. Fassnacht M, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-G34.
6. Pivonello R, et al. Medical treatment of Cushing's disease: an overview of the current and new therapeutic options. Neuroendocrinology. 2016;103(1):15-31.
7. Valassi E, et al. The effect of treatment for Cushing's syndrome on comorbidities: an observational study. J Clin Endocrinol Metab. 2012;97(10):E1828-E1838.
